Skip to main content Skip to section navigation Skip to footer
Back to AchieveLifeSciences.com
Achieve Life Sciences, Inc. Investor Relations
  • Investors
  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Information

Press Releases

News & Events

News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 11, 2023 8:00am EDT

Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

Sep 07, 2023 8:00am EDT

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 14, 2023 4:00pm EDT

Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update

Aug 01, 2023 8:00am EDT

Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast

Jul 18, 2023 8:00am EDT

Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting

Jul 11, 2023 11:23am EDT

Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

Jun 06, 2023 8:00am EDT

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

May 25, 2023 9:00am EDT

Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering

May 23, 2023 6:00am EDT

Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

May 17, 2023 8:00am EDT

Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • …Page 18
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Achieve Life Sciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap